Journal
NATURE REVIEWS NEUROLOGY
Volume 17, Issue 2, Pages 104-118Publisher
NATURE PORTFOLIO
DOI: 10.1038/s41582-020-00434-z
Keywords
-
Categories
Funding
- National Health and Medical Research Council of Australia [1132524, 1095127, 1153439]
- NHMRC [1156093]
- ALS Finding a Cure Foundation
- United Kingdom Medical Research Council under the JPND [MR/R024804/1]
- Motor Neurone Disease Association
- National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London
- Ada Health
- AstraZeneca
- Baillie Gifford
- Bold Health
- Camoni
- Compass Pathways
- Coronna
- EIT
- Happify
- HealthUnlocked
- Inbeeo
- Kheiron Medical
- Sano Genetics
- Self Care Catalysts
- Learning Corp
- Wellcome Trust
- VeraSci
- Woebot
Ask authors/readers for more resources
Researchers emphasize that a better understanding of the biological processes in amyotrophic lateral sclerosis has led to the identification of pathogenic targets and an increasing likelihood of effective therapies. Additionally, advancements in precision medicine and improved clinical trial designs will facilitate the acceleration of therapeutic approaches.
Individuals who are diagnosed with amyotrophic lateral sclerosis (ALS) today face the same historically intransigent problem that has existed since the initial description of the disease in the 1860s - a lack of effective therapies. In part, the development of new treatments has been hampered by an imperfect understanding of the biological processes that trigger ALS and promote disease progression. Advances in our understanding of these biological processes, including the causative genetic mutations, and of the influence of environmental factors have deepened our appreciation of disease pathophysiology. The consequent identification of pathogenic targets means that the introduction of effective therapies is becoming a realistic prospect. Progress in precision medicine, including genetically targeted therapies, will undoubtedly change the natural history of ALS. The evolution of clinical trial designs combined with improved methods for patient stratification will facilitate the translation of novel therapies into the clinic. In addition, the refinement of emerging biomarkers of therapeutic benefits is critical to the streamlining of care for individuals. In this Review, we synthesize these developments in ALS and discuss the further developments and refinements needed to accelerate the introduction of effective therapeutic approaches. The identification of pathogenic targets in amyotrophic lateral sclerosis means that effective therapies are increasingly likely. In this Review, Kiernan et al. discuss advances towards therapy and the innovations needed in clinical trials to facilitate the translation into treatments for patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available